贝伐珠单抗联合化疗在非小细胞肺癌患者中的应用效果

Application effects of Bevacizumab combined with chemotherapy in patients with non-small cell lung cancer

目的:分析贝伐珠单抗联合化疗在非小细胞肺癌(NSCLC)患者中的应用效果。方法:回顾性分析2021年11月至2023年10月该院收治的68例NSCLC患者的临床资料,根据治疗方法不同将其分为对照组和观察组各34例。对照组采取培美曲塞+顺铂化疗方案治疗,观察组在对照组基础上联合贝伐珠单抗治疗,比较两组疾病控制率(DCR),治疗前后肿瘤标志物[癌胚抗原(CEA)、细胞角蛋白19片段抗原21-1(CYFRA21-1)、糖类抗原125(CA125)]、T细胞亚群指标(CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+))水平,以及不良反应发生率。结果:观察组DCR为85.29%(29/34),高于对照组的58.82%(20/34),差异有统计学意义(P<0.05);治疗后,两组CEA、CYFRA21-1、CA125水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);治疗后,两组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平均低于治疗前,但观察组高于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:贝伐珠单抗联合化疗可提高NSCLC患者的DCR,降低肿瘤标志物水平,改善T细胞亚群指标水平,效果优于单纯化疗。

Objective:To analyze application effects of Bevacizumab combined with chemotherapy in patients with non-small cell lung cancer(NSCLC).Methods:The clinical data of 68 patients with NSCLC admitted to this hospital from November 2021 to October 2023 were retrospectively analyzed.According to different treatment methods,they were divided into control group and observation group,34 cases in each group.The control group was treated with Pemetrexed+Cisplatin chemotherapy,while the observation group was treated with Bevacizumab on the basis of that of the control group.The disease control rate(DCR),the levels of tumor markers[carcinoembryonic antigen(CEA),cytokeratin 19 fragment antigen 21-1(CYFRA21-1),carbohydrate antigen 125(CA125)]and T cell subsets(CD3^(+),CD4+,CD4+/CD8^(+))before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The DCR of the observation group was 85.29%(29/34),which was higher than 58.82%(20/34)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of CEA,CYFRA21-1 and CA125 in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of CD3^(+),CD4+,CD4+/CD8^(+)in the two groups were lower than those before the treatment,but those in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Bevacizumab combined with chemotherapy can improve the DCR of the NSCLC patients,reduce the levels of tumor markers,and improve the levels of T cell subsets.Moreover,it is superior to simple chemotherapy.